Table 3.
Completed phase II trials of antiangiogenic agents in gynecological cancers
| ID | Cancer/condition | No. | Intervention | ORR (%) | mPFS (mon.) | mOS (mon.) | SAEs (%) | Refs |
|---|---|---|---|---|---|---|---|---|
| NCT00025233 | CC/persistent or recurrent | 46 | Bevacizumab | 10.9 | 3.4 | 7.29 | 58.7 | 45 |
| NCT00548418 GSK107278 | CC/persistent or recurrent | 27 | Bevacizumab + topotecan + cisplatin | 59 | 7.1 | 13.2 | 44.44 | 46 |
| NCT00369122 RTOG0417 | CC/stage Ib–IIIb | 60 | Bevacizumab + cisplatin + radiotherapy | 68.7 | – | – | 22.03 | 49 |
| – | CC/advanced or recurrent | 34 | Bevacizumab + PC | 88 | 9 | 26 | – | 47 |
| NCT00937560 OCTAVIA | OC/stage IIb–IV | 189 | Bevacizumab + PC | 84.6 | 23.7 | – | 22.8 | 396 |
| NCT01010126 | EC/stage III–IV | 26 | Bevacizumab + temsirolimus | 25.1 | 6.0 | 11.5 | 61.5 | 60,339 |
| OC/stage III–IV | 58 | 6.4 | 5.6 | 16.3 | 58.6 | |||
| NCT01305213 GOG-0186I | OC/recurrent | 107 | (1) Bevacizumab | 28.2 | 4.8 | – | 16.98 | 397 |
| (2) Bevacizumab + fosbretabulin | 35.7 | 7.3, P = 0.05 | 29.6 | |||||
| NCT00696670 | OC/resistant | 39 | Bevacizumab + erlotinib | 23.1 | 4 | – | 30 | 398 |
| NCT00945139 | OC/platinum-resistant recurrent | 46 | Bevacizumab + PLD | 30.2 | 6.6 | 33.2 | 6.52 | 399 |
| NCT01091259 | OC/recurrent | 29 | Bevacizumab + irinotecan | 27.6 | 6.8 | 15.4 | 31 | 400 |
| NCT00886691 GOG-0186G | OC/recurrent | 150 | (1) Bevacizumab | 12.1 | 4.5 | 17.3 | 32 | 401 |
| (2) Bevacizumab + temsirolimus | 22.2 | 5.9, P = 0.39 | 16.6, P = 0.55 | 46.7 | ||||
| NCT00407563 ACORN | OC/platinum-resistant recurrent | 48 | Bevacizumab + abraxane | 50 | 8.08 | 17.15 | 27.1 | 402 |
| NCT00267696 OSU-05070 | OC/platinum-resistant recurrent | 45 | Bevacizumab + GC | 69 | 13.3 | 36.1 | 8.9 | 403 |
| NCT00977574 GOG-0086P | EC/stage III–IV | 339 | (1) Bevacizumab + PC | 60 | – | 34 | 42.9 | 404 |
| (2) Temsirolimus + PC | 55 | 25 | 50.4 | |||||
| (3) Bevacizumab + carboplatin | 53 | 25.2 | 46.5 | |||||
| NCT01770171 MITO END-2 | EC/advanced or recurrent | 108 | (1) PC | 53.1 | 10.5 | 29.7 | – | 54 |
| (2) PC + bevacizumab | 74.4 | 13.7, P = 0.43 | 40.0, P = 0.24 | |||||
| NCT01005329 RTOG 0921 | EC/high risk | 34 | Bevacizumab + cisplatin + radiotherapy | The 2-year estimate of OS was 96.7% | 26.7 | 53 | ||
| NCT00879359 | EC/advanced or recurrent | 15 | Bevacizumab + PC | 73 | 18 | 58 | 73.3 | 52 |
| NCT00723255 GOG-0229G | EC/recurrent | 43 | Bevacizumab + temsirolimus | 24.5 | 5.6 | 16.9 | 63.3 | 405 |
| NCT00301964 GOG-0229E | EC/persistent or recurrent | 56 | Bevacizumab | 13.5 | 4.2 | 10.5 | 34.6 | 51 |
| - | EC/persistent or recurrent | 46 | Bevacizumab + pemetrexed | 41 | 7.9 | 25.7 | 52 | 406 |
| NCT01468909 | OC/recurrent | 106 | (1) Paclitaxel | 31.8 | 7.5 | 23.3 | 30.00 | 407 |
| (2) Pazopanib + paclitaxel | 22.7 | 6.2, P = 0.20 | 20.7, P = 0.90 | 42.31 | ||||
| NCT01644825 MITO-11 | OC/stage Ic–IV | 74 | (1) Paclitaxel | 25 | 6.5 | – | 34 | 408 |
| (2) Pazopanib + paclitaxel | 56 | 16.1, P <0.01 | 46 | |||||
| NCT00430781 | CC/stage IVb, persistent, or recurrent | 230 | (1) Pazopanib | 9 | 4.22 | – | 37.84 | 257 |
| (2) Lapatinib | 5 | 3.99, P = 0.013 | 29 | |||||
| NCT02055690 | OC/recurrent | 21 | (1) Pazopanib | 22 | 3.7 | – | – | 45 |
| (2) Pazopanib + fosbretabulin | 18 | 7.6, P = 0.08 | ||||||
| NCT01669798 | OC/recurrent, bevacizumab-resistant | 27 | Nintedanib | 7.4 | 1.8 | 16 | 22.2 | 68 |
| NCT01225887 GOG-0229K | EC/recurrent | 37 | Nintedanib | 9.4 | 3.3 | 10.1 | 43.8 | 69 |
| NCT01210222 GOG-0229L | EC/recurrent | 35 | Trebananib | 3.1 | 1.7 | 6.6 | 43 | 82 |
| NCT01253681 | OC/recurrent | 61 | (1) Placebo | 27 | 4.6 | – | 64 | 409 |
| (2) Trebananib | 19 | 5.7 | 55 | |||||
| (3) Trebananib + paclitaxel | 37 | 7.2 | 65 | |||||
| NCT01111461 | EC/recurrent | 133 | Lenvatinib | 14.3 | 5.4 | 10.6 | 46.62 | 410 |
| NCT00278343 | OC/recurrent | 74 | Cediranib | 26 | 4.9 | 18.9 | 6.8 | 72 |
| NCT01132820 GOG-0229J | EC/recurrent | 48 | Cediranib | 12.5 | 3.65 | 12.5 | 41.7 | 74 |
| NCT00888173 GOG-0229I | EC/recurrent | 43 | Brivanib | 7 | 3.3 | 10.7 | 41.86 | 95 |
| NCT01267253 GOG-0227G | CC/recurrent | 28 | Brivanib | 8 | 3.2 | 7.9 | 50 | 94 |
| NCT02867956 | OC/platinum-refractory | 35 | Apatinib + etoposide | 54 | – | – | 5.7 | 87 |
| NCT02867956 | OC/recurrent | 29 | Apatinib | 41.4 | 5.1 | 14.5 | 31 | 86 |
| NCT00979992 GOG-0254 | OC/clear cell, recurrent or persistent | 30 | Sunitinib | 6.7 | 2.7 | 12.8 | – | 91 |
| NCT00388037 | OC/recurrent | 30 | Sunitinib | 3.3 | 4.1 | – | 50.00 | 90 |
| NCT00543049 AGO 2.11 | OC/platinum-resistant recurrent | 76 | Sunitinib (noncontinuous/continuous) | 16.7/5.4 | 4.8/4.9 | 13.6/13.7 | – | 89 |
| NCT00768144 | OC/recurrent, platinum-refractory | 35 | Sunitinib | 8.3 | 9.9 | – | 19.44 | 88 |
| NCT00478426 | EC/metastatic or recurrent | 33 | Sunitinib | 18.1 | 3 | 19.4 | 52 | 92 |
| NCT00389974 | CC/advance or metastatic | 19 | Sunitinib | 0 | 3.5 | – | 73.68 | 93 |
ORR objective response rate